ON
🔍
← Back to feed
United StatesBusiness6 days ago

STAT+: Lilly’s Ajax acquisition may have been worth it

The article discusses recent developments in biotechnology, including a syphilis drug shortage affecting pregnant women in Arizona, the FDA's approval of Sanofi's diabetes drug Tzield following a contentious review, and the Trump administration's proposal to close a Medicare negotiation loophole.

A syphilis drug shortage, Sanofi’s diabetes drug approval, and more biotech news from The Readout

ANGELA WEISS / AFP via Getty Images

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox.

A worsening shortage of Bicillin, Pfizer’s injectable form of penicillin, left an Arizona woman unable to receive timely treatment for syphilis during pregnancy.

Also, the FDA approved Sanofi’s diabetes drug Tzield after an unusually contentious review process, and the Trump administration has proposed closing a Medicare negotiation loophole.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter .

Read the full article at STAT News →
Source document: FDA approval of Sanofi's Tzield

1 reports

STAT NewsIndependentCenter6 days ago
STAT+: Lilly’s Ajax acquisition may have been worth it

The article discusses recent developments in biotechnology, including a syphilis drug shortage affecting pregnant women in Arizona, the FDA's approval of Sanofi's diabetes drug Tzield following a contentious review, and the Trump administration's proposal to close a Medicare negotiation loophole.

Bias read (Center): The article presents factual updates on biotech-related issues without overtly favoring any political side. It mentions policy proposals from the Trump administration but does not provide commentary or framing that suggests a particular ideological leaning.

Official sources cited

  • government FDA approval of Sanofi's Tzield
  • government Trump administration proposal to close Medicare negotiation loophole

Go to the primary sources (2)

The official sources this coverage is built on. Read them directly to bypass framing.

  • governmentFDA approval of Sanofi's Tzield
  • governmentTrump administration proposal to close Medicare negotiation loophole